Nanodiamond and Nanoplatinum Liquid, DPV576, Activates Human Monocyte-derived Dendritic Cells In Vitro
Charles Drew University of Medicine and Science, Department of Otolaryngology, Los Angeles, California 90059, USA. Anticancer research
(Impact Factor: 1.83).
The influence of nanoparticles on the immune system is poorly understood. It was recently shown that exposure to a mixture of nanodiamond (ND)- and nanoplatinum (NP)-coated material (DPV576-C) activates murine T-cells. This study examined the role of a dispersed aqueous mixture of ND/NP (DPV576) in activating human dendritic cells (DCs) in vitro.
Human monocyte-derived DCs were treated with DPV576 at various concentrations (50, 100 and 200 μg/ml) for 24 hours in vitro. Activation of DCs was determined by assessing the expression of co-stimulatory and maturation markers (CD80, CD83, CD86, HLADR), production of cytokines, and induction of proliferation of naïve CD4 T-cells. Expression of co-stimulatory molecules and cell proliferation were analysed by flow cytometry and cytokine secretion by ELISA.
DPV576 treatment of DCs resulted in: (i) increased CD83 and CD86 expression on DCs, (ii) up-regulation in the levels of DC-secreted cytokines IL-6, TNF and IL-10, and (iii) increased ability to induce proliferation in CD4(+) T-cells which is associated with increased expression of T-cell activation marker CD25.
Solution containing ND/NP (DPV576) activated human DCs and DCs-driven CD4 naive T-cell proliferation in vitro, which may be useful in boosting immune responses in cancer treatment.
Available from: Alia Ghoneum
- "These considerations prompted us to investigate a new modulator of MDR with lower toxicity. Earlier studies showed that a mixture of two nanoparticles - nanodiamond (ND) and nanoplatinum (NP) - in liquid form (DPV576) and in fabric form (DPV576-C), show immune modulatory effects.21,22 In the current study we extend our research with DPV576 to examine its chemo-sensitizing activity against DNR-resistant human myeloid leukemia (HL60/AR) in vitro. "
[Show abstract] [Hide abstract]
ABSTRACT: Recently nanoparticles have been extensively studied and have proven to be a promising candidate for cancer treatment and diagnosis. In the current study, we examined the chemo-sensitizing activity of a mixture of nanodiamond (ND) and nanoplatinum (NP) solution known as DPV576, against multidrug-resistant (MDR) human myeloid leukemia (HL60/AR) and MDR-sensitive cells (HL60). Cancer cells were cultured with different concentrations of daunorubicin (DNR) (1 × 10 (-9)-1 × 10 (-6) M) in the presence of selected concentrations of DPV576 (2.5%-10% v/v). Cancer cell survival was determined by MTT assay, drug accumulation by flow cytometry and confocal laser scanning microscopy (CLSM), and holes and structural changes by atomic force microscopy (AFM). Co-treatment of HL60/AR cells with DNR plus DPV576 resulted in the reduction of the IC50 to 1/4th. This was associated with increased incidences of holes inside the cells as compared with control untreated cells. On the other hand, HL60 cells did not show changes in their drug accumulation post-treatment with DPV576 and DNR. We conclude that DPV576 is an effective chemo-sensitizer as indicated by the reversal of HL60/AR cells to DNR and may represent a potential novel adjuvant for the treatment of chemo-resistant human myeloid leukemia.
Available from: Jeroen Vanoirbeek
[Show abstract] [Hide abstract]
ABSTRACT: Evaluation of the immunomodulatory potentials of nanomaterials is essential for developing safe and consumer-friendly nanotechnology. Various nanomaterials interact with the immune system, in a beneficial or deleterious way, but mechanistic details about such interactions are scarce. A lack of agreed-upon guidelines for evaluating the immunotoxicity of nanoparticles (NPs) adds to the complexity of the issue. Various review articles have summarized the immune system interactions of biodegradable NPs (with pharmaceutical uses), but such information is largely lacking for nonbiodegradable NPs. Here we give an overview of interactions of nonbiodegradable, persistent NPs with the immune system. Particular emphases include key factors that shape such interactions, cell-specific responses, allergy and immune-sensitive respiratory disorders. WIREs Nanomed Nanobiotechnol 2012, 4:169–183. doi: 10.1002/wnan.166
For further resources related to this article, please visit the WIREs website.
[Show abstract] [Hide abstract]
ABSTRACT: Nanoscale objects, whether of biologic origin or synthetically created, are being developed into devices for a variety of bionanotechnology diagnostic and pharmaceutical applications. However, the potential immunotoxicity of these nanomaterials and mechanisms by which they may induce adverse reactions have not received sufficient attention. Nanomaterials, depending on their characteristics and compositions, can interact with the immune system in several ways and either enhance or suppress immune system function. Cytokines perform pleiotropic functions to mediate and regulate the immune response and are generally recognized as biomarkers of immunotoxicity. While the specificity and validity of certain cytokines as markers of adverse immune response has been established for chemicals, small and macromolecular drugs, research on their applicability for predicting and monitoring the immunotoxicity of engineered nanomaterials is still ongoing. The goal of this review is to provide guidelines as to important cytokines that can be utilized for evaluating the immunotoxicity of nanomaterials and to highlight the role of those cytokines in mediating adverse reactions, which is of particular importance for the clinical development of nanopharmaceuticals and other nanotechnology-based products. Importantly, the rational design of nanomaterials of low immunotoxicity will be discussed, focusing on synthetic nanodevices, with emphasis on both the nanoparticle-forming materials and the embedded cargoes.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.